{"id":"cefroxadine","rwe":[{"pmid":"38334389","year":"2024","title":"Do dietary interventions exert clinically important effects on the bioavailability of β-lactam antibiotics? A systematic review with meta-analyses.","finding":"","journal":"The Journal of antimicrobial chemotherapy","studyType":"Clinical Study"},{"pmid":"16137854","year":"2006","title":"A specific and rapid HPLC assay for the determination of cefroxadine in human plasma and its application to pharmacokinetic study in Korean.","finding":"","journal":"Journal of pharmaceutical and biomedical analysis","studyType":"Clinical Study"},{"pmid":"15747584","year":"2004","title":"[Antibacterial activity of oral cephems against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].","finding":"","journal":"The Japanese journal of antibiotics","studyType":"Clinical Study"},{"pmid":"10443470","year":"1999","title":"pH-dependent inhibitory effects of angiotensin-converting enzyme inhibitors on cefroxadine uptake by rabbit small intestinal brush-border membrane vesicles and their relationship with hydrophobicity and the ratio of zwitterionic species.","finding":"","journal":"Biological & pharmaceutical bulletin","studyType":"Clinical Study"},{"pmid":"9145229","year":"1997","title":"Inhibitory effects of angiotensin-converting enzyme inhibitor on cefroxadine uptake by rabbit small intestinal brush border membrane vesicles.","finding":"","journal":"Biological & pharmaceutical bulletin","studyType":"Clinical Study"}],"tags":[{"label":"cefroxadine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01DB11","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"cefroxadin","offLabel":[],"synonyms":["CGP-9000","CGP 9000","cefroxadin","cefroxadine"],"timeline":[],"brandName":"Cefroxadin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"cefroxadine","explanation":"Imagine the bacterial cell wall as a brick wall. Cefroxadine blocks the enzyme that helps build the wall, causing the wall to weaken and eventually collapse, leading to the death of the bacterial cell.","oneSentence":"Cefroxadine works by inhibiting the bacterial enzyme responsible for cell wall synthesis.","technicalDetail":"Cefroxadine exerts its antibacterial effect by binding to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, thereby inhibiting the transpeptidation reaction necessary for cell wall synthesis and ultimately leading to cell lysis."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/557","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CEFROXADINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEFROXADINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:17:31.225085","biosimilars":[],"competitors":[{"drugName":"cefalexin","drugSlug":"cefalexin","fdaApproval":"1971-01-04","relationship":"same-class"},{"drugName":"cefalotin","drugSlug":"cefalotin","fdaApproval":"1974-12-18","relationship":"same-class"},{"drugName":"cefazolin","drugSlug":"cefazolin","fdaApproval":"1973-10-04","genericCount":20,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefadroxil","drugSlug":"cefadroxil","fdaApproval":"1978-02-17","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefapirin","drugSlug":"cefapirin","fdaApproval":"1974-03-12","relationship":"same-class"},{"drugName":"cefradine","drugSlug":"cefradine","fdaApproval":"1974-08-19","relationship":"same-class"}],"genericName":"cefroxadine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cefalexin","brandName":"cefalexin","genericName":"cefalexin","approvalYear":"1971","relationship":"same-class"},{"drugId":"cefalotin","brandName":"cefalotin","genericName":"cefalotin","approvalYear":"1974","relationship":"same-class"},{"drugId":"cefazolin","brandName":"cefazolin","genericName":"cefazolin","approvalYear":"1973","relationship":"same-class"},{"drugId":"cefadroxil","brandName":"cefadroxil","genericName":"cefadroxil","approvalYear":"1978","relationship":"same-class"},{"drugId":"cefapirin","brandName":"cefapirin","genericName":"cefapirin","approvalYear":"1974","relationship":"same-class"},{"drugId":"cefradine","brandName":"cefradine","genericName":"cefradine","approvalYear":"1974","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03877289","phase":"PHASE4","title":"Efficacy of Oxybutynin in Paediatric Cystitis","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2008-10","conditions":["Cystitis"],"enrollment":81,"completionDate":"2014-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"010923","UNII":"B908C4MV2R","CHEBI":"CHEBI:31379","INN_ID":"4722","UMLSCUI":"C0108941","ChEMBL_ID":"CHEMBL3186538","KEGG_DRUG":"D01528","DRUGBANK_ID":"DB11367","PUBCHEM_CID":"5284529","MESH_SUPPLEMENTAL_RECORD_UI":"C012671"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.74 hours","clearance":"4.78 mL/min/kg","fractionUnbound":"0.1%","volumeOfDistribution":"0.17 L/kg"},"publicationCount":74,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J01DB11","allCodes":["J01DB11"]},"biosimilarFilings":[],"recentPublications":[{"date":"2024 Apr 2","pmid":"38334389","title":"Do dietary interventions exert clinically important effects on the bioavailability of β-lactam antibiotics? A systematic review with meta-analyses.","journal":"The Journal of antimicrobial chemotherapy"},{"date":"2006 Feb 13","pmid":"16137854","title":"A specific and rapid HPLC assay for the determination of cefroxadine in human plasma and its application to pharmacokinetic study in Korean.","journal":"Journal of pharmaceutical and biomedical analysis"},{"date":"2004 Dec","pmid":"15747584","title":"[Antibacterial activity of oral cephems against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].","journal":"The Japanese journal of antibiotics"},{"date":"1999 Jul","pmid":"10443470","title":"pH-dependent inhibitory effects of angiotensin-converting enzyme inhibitors on cefroxadine uptake by rabbit small intestinal brush-border membrane vesicles and their relationship with hydrophobicity and the ratio of zwitterionic species.","journal":"Biological & pharmaceutical bulletin"},{"date":"1997 Apr","pmid":"9145229","title":"Inhibitory effects of angiotensin-converting enzyme inhibitor on cefroxadine uptake by rabbit small intestinal brush border membrane vesicles.","journal":"Biological & pharmaceutical bulletin"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cefroxadin is a small molecule antibiotic. It has been studied in clinical trials for the treatment of cystitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}